Reisediarrhö

Traveler‘s diarrhea

Zusammenfassung

Die Reisediarrhö ist die häufigste Krankheit des Fernreisenden und kommt bei 10–50 % dieser Zielgruppe vor. Bei gut 90 % der Diarrhöepisoden klingen die Beschwerden innerhalb von 3 bis 5 Tagen ohne Komplikationen ab. Es ist jedoch wichtig, komplikationsträchtige Verläufe zu erfassen und rasch zu therapieren. Enterotoxinbildende E.-coli-Stämme (ETEC) sind die wichtigsten Erreger der Reisediarrhö mit einer Häufigkeit von 30–40 %. Zur Therapie sind Rehydratationsmaßnahmen obligat; Motilitätshemmer und Antibiotika können die Erkrankungsdauer verkürzen. Die Möglichkeiten einer Prophylaxe sind limitiert, dennoch sollte über Nahrungsmittelhygiene beraten werden. Der prophylaktische Einsatz von Antibiotika oder einer Immunisierung kommt nur für gezielte Risikogruppen infrage.

Abstract

Traveler’s diarrhea is the most frequent health problem for travelers to the tropics and occurs in 10–50 % of this target group. In about 90 % of cases diarrheal symptoms stop within 3–5 days without complications, but it is important to detect severe courses and treat them immediately. Enterotoxigenic Escherichia coli strains (ETEC) are the most frequent pathogens causing traveler’s diarrhea with a frequency of 30–40 %. Rehydration measures are the basis of therapy and anti-motility agents and antibiotics may shorten the duration of the disease. Prophylactic measures are limited in efficacy, but advice on food hygiene rules should be given. The prophylactic use of antibiotics or immunization is only warranted in special risk groups.

This is a preview of subscription content, log in to check access.

Weiterführende Literatur

  1. 1.

    Apelt N, Hartberger C, Campe H, Löscher T (2010) The prevalence of norovirus in returning international travelers with diarrhea. BMC Infect Dis 10:131. DOI 10.1186/1471-2334-10-131

    PubMed Central  PubMed  Article  Google Scholar 

  2. 2.

    Behrens RH, Cramer JP, Jelinek T et al (2014) Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers‘ diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. Lancet Infect Dis 14:197–204

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Burchard GD, Hentschke M, Weinke T et al (2013) Reisediarrhoe. Dtsch Med Wochenschr 138:1673–1678

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    DuPont HL (2012) Approach to the patient with infectious colitis. Curr Opin Gastroenterol 28:39–46

    PubMed  Article  Google Scholar 

  5. 5.

    DuPont HL, Ericsson CD, Farthing MJ et al (2009) Expert review of the evidence base for self-therapy of travelers‘ diarrhea. J Travel Med 16:161–171

    PubMed  Article  Google Scholar 

  6. 6.

    Ericsson CD (2003) Travellers‘ diarrhoea. Int J Antimicrob Agents 21:116–124

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Irving PM, Gibson PR (2008) Infections and IBD. Nat Clin Pract Gastroenterol Hepatol 5:18–27

    PubMed  Article  Google Scholar 

  8. 8.

    Jiang ZD, Dupont HL, Brown EL et al (2010) Microbial etiology of travelers‘ diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic Bacteroides fragilis and Arcobacter species. J Clin Microbiol 48:1417–1419

    PubMed Central  PubMed  Article  Google Scholar 

  9. 9.

    Lundkvist J, Steffen R, Jonsson B (2009) Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers‘ diarrhea. J Travel Med 16:28–34

    PubMed  Article  Google Scholar 

  10. 10.

    Murphy H, Pandey P (2012) Pathogens for travelers‘ diarrhea in Nepal and resistance patterns. Curr Infect Dis Rep 14:238–245

    PubMed  Article  Google Scholar 

  11. 11.

    Okhuysen PC (2005) Current concepts in travelers‘ diarrhea: epidemiology, antimicrobial resistance and treatment. Curr Opin Infect Dis 18:522–526

    PubMed  Article  Google Scholar 

  12. 12.

    Pitzurra R, Fried M, Rogler G et al (2011) Irritable bowel syndrome among a cohort of European travelers to resource-limited destinations J Travel Med 18:250–256

  13. 13.

    Rendi-Wagner P, Kollaritsch H (2002) Drug prophylaxis for travelers‘ diarrhea. Clin Inf Dis 34:628–633

    Article  Google Scholar 

  14. 14.

    Shah N, Du Pont HL, Ramsey DJ (2009) Global etiology of travelers‘ diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg 80:609–614

    PubMed  Google Scholar 

  15. 15.

    Steffen R, Acar J, Walker E, Zuckerman J (2003) Cholera: assessing the risk to travellers and identifying methods of protection. Trav Med Inf Dis 1:80–88

    Article  Google Scholar 

  16. 16.

    Swaminathan A, Torresi J, Schlagenhauf P et al (2009) A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. J Infect 59:19–27

    PubMed  Article  Google Scholar 

  17. 17.

    Taylor DN, Bourgeois AL, Ericsson CD et al (2006) A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers‘ diarrhea. Am J Trop Med Hyg 74:1060–1066

    CAS  PubMed  Google Scholar 

  18. 18.

    Von Sonnenburg F, Tornieporth N, Waiyaki P et al (2000) Risk and aetiology of diarrhoea at various tourist destinations. Lancet 356:133–134

    Article  Google Scholar 

  19. 19.

    Weinke T, Liebold I, Burchard GD et al (2008) Prophylactic immunisation against traveller’s diarrhoea caused by enterotoxin-forming strains of Escherichia coli and against cholera: does it make sense and for whom? Travel Med Infect Dis 6:362–367

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Weinke T, Liebold I (2013) Intestinale Protozoeninfektionen. Dtsch Med Wochenschr 138:709–711

    CAS  PubMed  Article  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. T. Weinke: Vortragshonorare folgender Firmen: Astellas, Falk Foundation, Norgine, Novartis; I. Liebold: Vortragshonorare folgender Firmen: BMS, Falk Foundation, Pfizer. Der Beitrag enthält keine Studien an Menschen oder Tieren.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Prof. Dr. T. Weinke.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Weinke, T., Liebold, I. Reisediarrhö. Gastroenterologe 9, 366–371 (2014). https://doi.org/10.1007/s11377-014-0882-7

Download citation

Schlüsselwörter

  • Gastrointestinale Infektion
  • Escherichia-coli-Infektionen
  • Protozoen
  • Toxine
  • Rehydration

Keywords

  • Gastrointestinal infection
  • Escherichia coli infections
  • Protozoa
  • Toxins
  • Rehydration